Triple Analysis: Lymphoma, Protein Kinase Inhibitors and AntibodiesBioSeeker Group ABNovember 1, 2012 6255 Pages - SKU: BIOS4910053 |
- Key Topics Covered:
- Part I: Lymphoma
- 5.1 The Scope of this Report 26
- 6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
- 8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
- 9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
- 11 Disclaimer 939
- 12 Drug Index 940
- 13 Company Index 948
- Figures: Includes 6 Figures
- Tables: Includes 222 Tables
- Total Number of Pages: 954
- Part II: Protein Kinase Inhibitors
- 5.1 The Scope of this Report 38
- 6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
- 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
- 9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
- 11 Disclaimer 2940
- Figures: Includes 8 Figures
- Tables: Includes 389 Tables
- Total Number of Pages: 2,940
- Part III: Antibodies
- 5.1 The Scope of this Report 35
- 6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
- 7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
- 8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
- 10 Disclaimer 2361
- Figures: Includes 7 Figures
- Tables: Includes 355 Tables
- Total Number of Pages: 2,361
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Oncology/Hematology Reports